Vancouver, British Columbia, Canada – June 15, 2017 – Vanc Pharmaceuticals, Inc. (“Vanc“) responded today to a demand letter from Canagen Pharmaceuticals Inc. (“Canagen“), in which Canagen claims compensation from Vanc of $510,000. Vanc believes that the claims are wholly without merit, and intends to vigorously defend its position if an action is commenced. Vanc […]
June 1, 2017 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the “OTC”) markets announces today that 11 of the Company’s generic molecules have been listed with the major national distributor and wholesaler of drugs in Canada. “I am very pleased to announce that […]
May 17, 2017 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the “OTC”) markets, announces today it has entered into a Canada-wide distribution agreement for INSTI® HIV-1/HIV-2 Antibody Test (INSTI). “We are very pleased to have acquired the Canadian distribution rights to INSTI,” commented […]
May 12, 2017 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the “OTC”) markets, is pleased to announce a non-brokered private placement of up to 10,000,000 units of the Company at a price of $0.15 per unit (the “Units”) for gross proceeds of up […]
April 20, 2017 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the “OTC”) markets is pleased to announce the appointment of Mr. Alan Arnstein to VANC’s Board of Directors. “We are delighted to have Mr. Arnstein join our company and believe it is a […]
March 24, 2017 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the “OTC”) markets provides marketing update as part of its ongoing program to bring value added products to the Canadian pharmacy industry. “I am pleased to announce that VANC’s premium natural iron supplement […]
February 27, 2017 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the “OTC”) markets announces the launch of a new OTC laxative to the market place. Sennace represents another in a series of OTC products
February 7, 2017 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the “OTC”) markets announces the Company has hired two directors of sales for both eastern Canada and western Canada. “I am pleased to announce the successful recruitment of two pharmaceutical sales experts, Devin […]
January 31, 2017 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the “OTC”) markets, provides the following update from Bob Rai, Interim CEO of VANC: As we begin 2017, I am proud to say that the Company is now seeing the fruits of some […]
January 30, 2017 – VANC Pharmaceuticals Inc. (“VANC” or the “Company”), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the “OTC”) markets, is pleased to announce a non-brokered private placement of up to 5,416,666 units of the Company at a price of $0.24 per unit (the “Units”) for gross proceeds of up […]
